Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE versus TERAZOL 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE versus TERAZOL 7.
Fluconazole vs TERAZOL 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane.
Terconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This disruption increases membrane permeability and leads to fungal cell death.
200-400 mg orally or intravenously once daily. For candidemia and other invasive Candida infections, loading dose of 800 mg (12 mg/kg) on day 1, then 400 mg (6 mg/kg) daily.
Intravaginal: One full applicator (approximately 5 g of cream containing 40 mg of terconazole) inserted vaginally once daily at bedtime for 7 consecutive days.
None Documented
None Documented
Clinical Note
moderateMethoxsalen + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Fluconazole
Terminal elimination half-life ~30 hours (range 20-50 h) in patients with normal renal function; prolonged in renal impairment (up to 98 h in CrCl <20 mL/min). This long half-life supports once-daily dosing and allows loading dose administration.
Terminal elimination half-life is approximately 7-10 hours; clinically, it allows for once-daily vaginal application, but systemic accumulation is minimal with vaginal dosing.
Renal: approximately 80% as unchanged drug; biliary/fecal: ~11% as metabolites and unchanged drug.
Primarily fecal (approximately 60%) as unchanged drug and metabolites; renal excretion accounts for about 20% (mostly metabolites).
Category C
Category C
Azole Antifungal
Azole Antifungal
"The metabolism of Fluconazole can be decreased when combined with Docetaxel."